

## REFERENCES

- [1] WHO. HIV/AIDS. Fact sheet No 360 2015.
- [2] Wherry EJ. T cell exhaustion. *Nat Immunol* 2011;12:492-9.
- [3] Cubas RA, Mudd JC, Savoye AL, Perreau M, van Grevenynghe J, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. *Nat Med* 2013;19:494-9.
- [4] Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. *PLoS Pathog* 2014;10:e1003853.
- [5] Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. *Curr Opin Immunol* 2000;12:375-80.
- [6] Crum-Cianflone NF, Iverson E, Defang G, Blair PJ, Eberly LE, et al. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. *Vaccine* 2011;29:3183-91.
- [7] Chotirosniramit N, Sugandhavesa P, Aurrpibul L, Thetket S, Kosashunhanan N, et al. Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand. *Hum Vaccin Immunother* 2012;8:1854-9.
- [8] Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. *Clin Infect Dis* 2011;52:138-46.

- [9] Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, et al. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children. *Vaccine* 2011;29:8705-11.
- [10] Whitaker JA, Roupael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. *Lancet Infect Dis* 2012;12:966-76.
- [11] Chinen J, Shearer WT. Molecular virology and immunology of HIV infection. *J Allergy Clin Immunol* 2002;110:189-98.
- [12] Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. *J Clin Virol* 2005;34:233-44.
- [13] Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. *Nat Rev Microbiol* 2008;6:143-55.
- [14] Freed EO, Martin MA. The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. *J Biol Chem* 1995;270:23883-6.
- [15] Bouvier NM, Palese P. The biology of influenza viruses. *Vaccine* 2008;26 Suppl 4:D49-53.
- [16] Nelson MI, Holmes EC. The evolution of epidemic influenza. *Nat Rev Genet* 2007;8:196-205.
- [17] Samji T. Influenza A: understanding the viral life cycle. *Yale J Biol Med* 2009;82:153-9.
- [18] Tong S, Zhu X, Li Y, Shi M, Zhang J, et al. New world bats harbor diverse influenza A viruses. *PLoS Pathog* 2013;9:e1003657.
- [19] Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Bat-derived influenza-like viruses H17N10 and H18N11. *Trends Microbiol* 2014;22:183-91.

- [20] Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. *Nat Rev Microbiol* 2005;3:591-600.
- [21] Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. *N Engl J Med* 2004;350:1118-29.
- [22] Glebe D, Urban S. Viral and cellular determinants involved in hepadnaviral entry. *World J Gastroenterol* 2007;13:22-38.
- [23] Taubenberger JK, Morens DM. The pathology of influenza virus infections. *Annu Rev Pathol* 2008;3:499-522.
- [24] Janeway CA, Jr., Medzhitov R. Innate immune recognition. *Annu Rev Immunol* 2002;20:197-216.
- [25] Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. *Nat Rev Immunol* 2014;14:315-28.
- [26] van de Sandt CE, Kreijtz JH, Rimmelzwaan GF. Evasion of influenza A viruses from innate and adaptive immune responses. *Viruses* 2012;4:1438-76.
- [27] Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. *J Biol Chem* 2005;280:5571-80.
- [28] Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* 2001;413:732-8.
- [29] Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 2004;303:1529-31.

- [30] Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. *Proc Natl Acad Sci U S A* 2004;101:5598-603.
- [31] Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, et al. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. *J Immunol* 2007;178:3368-72.
- [32] Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science* 2004;303:1526-9.
- [33] Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, et al. Cell type-specific involvement of RIG-I in antiviral response. *Immunity* 2005;23:19-28.
- [34] Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* 2006;314:997-1001.
- [35] Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, et al. 5'-Triphosphate RNA is the ligand for RIG-I. *Science* 2006;314:994-7.
- [36] Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. *Cell* 2010;140:397-408.
- [37] Baum A, Sachidanandam R, Garcia-Sastre A. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. *Proc Natl Acad Sci U S A* 2010;107:16303-8.
- [38] Kowalinski E, Lunardi T, McCarthy AA, Luber J, Brunel J, et al. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. *Cell* 2011;147:423-35.

- [39] Jiang F, Ramanathan A, Miller MT, Tang GQ, Gale M, Jr., et al. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. *Nature* 2011;479:423-7.
- [40] Luo D, Ding SC, Vela A, Kohlway A, Lindenbach BD, et al. Structural insights into RNA recognition by RIG-I. *Cell* 2011;147:409-22.
- [41] Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, et al. Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity. *J Virol* 2014;88:13990-4001.
- [42] Guarda G, Zenger M, Yazdi AS, Schroder K, Ferrero I, et al. Differential expression of NLRP3 among hematopoietic cells. *J Immunol* 2011;186:2529-34.
- [43] Pothlichet J, Meunier I, Davis BK, Ting JP, Skamene E, et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. *PLoS Pathog* 2013;9:e1003256.
- [44] Coates BM, Staricha KL, Wiese KM, Ridge KM. Influenza A Virus Infection, Innate Immunity, and Childhood. *JAMA Pediatr* 2015.
- [45] Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. *Nat Rev Microbiol* 2009;7:99-109.
- [46] Van Der Sluijs KF, Van Elden LJ, Arens R, Nijhuis M, Schuurman R, et al. Enhanced viral clearance in interleukin-18 gene-deficient mice after pulmonary infection with influenza A virus. *Immunology* 2005;114:112-20.
- [47] Schmitz N, Kurrer M, Bachmann MF, Kopf M. Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. *J Virol* 2005;79:6441-8.

- [48] Thomas PG, Dash P, Aldridge JR, Jr., Ellebedy AH, Reynolds C, et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. *Immunity* 2009;30:566-75.
- [49] Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. *PLoS Pathog* 2008;4:e1000017.
- [50] Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. *J Virol* 2010;84:5670-7.
- [51] Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C. Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. *Cell* 1986;44:147-58.
- [52] Hefti HP, Frese M, Landis H, Di Paolo C, Aguzzi A, et al. Human MxA protein protects mice lacking a functional alpha/beta interferon system against La crosse virus and other lethal viral infections. *J Virol* 1999;73:6984-91.
- [53] Turan K, Mibayashi M, Sugiyama K, Saito S, Numajiri A, et al. Nuclear MxA proteins form a complex with influenza virus NP and inhibit the transcription of the engineered influenza virus genome. *Nucleic Acids Res* 2004;32:643-52.
- [54] Pavlovic J, Arzet HA, Hefti HP, Frese M, Rost D, et al. Enhanced virus resistance of transgenic mice expressing the human MxA protein. *J Virol* 1995;69:4506-10.
- [55] Zurcher T, Pavlovic J, Staeheli P. Nuclear localization of mouse Mx1 protein is necessary for inhibition of influenza virus. *J Virol* 1992;66:5059-66.

- [56] Cilloniz C, Pantin-Jackwood MJ, Ni C, Carter VS, Korth MJ, et al. Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival. *J Virol* 2012;86:2437-46.
- [57] Silverman RH. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. *J Virol* 2007;81:12720-9.
- [58] Sadler AJ, Williams BR. Structure and function of the protein kinase R. *Curr Top Microbiol Immunol* 2007;316:253-92.
- [59] Murtaugh MP, Baarsch MJ, Zhou Y, Scamurra RW, Lin G. Inflammatory cytokines in animal health and disease. *Vet Immunol Immunopathol* 1996;54:45-55.
- [60] Seo SH, Webster RG. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. *J Virol* 2002;76:1071-6.
- [61] Pang IK, Ichinohe T, Iwasaki A. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. *Nat Immunol* 2013;14:246-53.
- [62] Lauder SN, Jones E, Smart K, Bloom A, Williams AS, et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. *Eur J Immunol* 2013;43:2613-25.
- [63] Denton AE, Doherty PC, Turner SJ, La Gruta NL. IL-18, but not IL-12, is required for optimal cytokine production by influenza virus-specific CD8+ T cells. *Eur J Immunol* 2007;37:368-75.
- [64] Sanders CJ, Doherty PC, Thomas PG. Respiratory epithelial cells in innate immunity to influenza virus infection. *Cell Tissue Res* 2011;343:13-21.
- [65] Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. *Virus Res* 2011;162:19-30.

- [66] Jost S, Altfeld M. Control of human viral infections by natural killer cells. *Annu Rev Immunol* 2013;31:163-94.
- [67] Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, et al. Recognition of viral hemagglutinins by NKp44 but not by NKp30. *Eur J Immunol* 2001;31:2680-9.
- [68] Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. *Nature* 2001;409:1055-60.
- [69] Batista FD, Harwood NE. The who, how and where of antigen presentation to B cells. *Nat Rev Immunol* 2009;9:15-27.
- [70] Cerutti A. The regulation of IgA class switching. *Nat Rev Immunol* 2008;8:421-34.
- [71] Wang NS, McHeyzer-Williams LJ, Okitsu SL, Burris TP, Reiner SL, et al. Divergent transcriptional programming of class-specific B cell memory by T-bet and RORalpha. *Nat Immunol* 2012;13:604-11.
- [72] Nutt SL, Tarlinton DM. Germinal center B and follicular helper T cells: siblings, cousins or just good friends? *Nat Immunol* 2011;12:472-7.
- [73] Boyden AW, Legge KL, Waldschmidt TJ. Pulmonary infection with influenza A virus induces site-specific germinal center and T follicular helper cell responses. *PLoS One* 2012;7:e40733.
- [74] Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. *Immunol Rev* 2013;251:177-88.
- [75] Liang B, Hyland L, Hou S. Nasal-associated lymphoid tissue is a site of long-term virus-specific antibody production following respiratory virus infection of mice. *J Virol* 2001;75:5416-20.



- [76] Manz RA, Hauser AE, Hiepe F, Radbruch A. Maintenance of serum antibody levels. *Annu Rev Immunol* 2005;23:367-86.
- [77] Gerhard W. The role of the antibody response in influenza virus infection. *Curr Top Microbiol Immunol* 2001;260:171-90.
- [78] Jegaskanda S, Reading PC, Kent SJ. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. *J Immunol* 2014;193:469-75.
- [79] Nayak DP, Hui EK, Barman S. Assembly and budding of influenza virus. *Virus Res* 2004;106:147-65.
- [80] Mozdzanowska K, Maiese K, Furchner M, Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. *Virology* 1999;254:138-46.
- [81] El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. *J Immunol* 2011;186:1022-31.
- [82] Neiryck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. *Nat Med* 1999;5:1157-63.
- [83] Wang Y, Zhou L, Shi H, Xu H, Yao H, et al. Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. *Biochem Biophys Res Commun* 2009;385:118-22.
- [84] Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, et al. M2e-based universal influenza A vaccine. *Vaccine* 2009;27:6280-3.

- [85] Sukeno N, Otsuki Y, Konno J, Yamane N, Odagiri T, et al. Anti-nucleoprotein antibody response in influenza A infection. *Tohoku J Exp Med* 1979;128:241-9.
- [86] Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. *J Virol* 2011;85:5027-35.
- [87] Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. *J Immunol* 2008;181:4168-76.
- [88] Bodewes R, Osterhaus AD, Rimmelzwaan GF. Targets for the induction of protective immunity against influenza A viruses. *Viruses* 2010;2:166-88.
- [89] Sambhara S, Kurichh A, Miranda R, Tumpey T, Rowe T, et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. *Cell Immunol* 2001;211:143-53.
- [90] Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, et al. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. *Infect Immun* 1982;36:1102-8.
- [91] Renegar KB, Small PA, Jr., Boykins LG, Wright PF. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. *J Immunol* 2004;173:1978-86.
- [92] van Riet E, Aina A, Suzuki T, Hasegawa H. Mucosal IgA responses in influenza virus infections; thoughts for vaccine design. *Vaccine* 2012;30:5893-900.
- [93] Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, et al. Protection against influenza virus infection in polymeric Ig receptor

knockout mice immunized intranasally with adjuvant-combined vaccines. *J Immunol* 2002;168:2930-8.

- [94] Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, et al. Immunobiology of dendritic cells. *Annu Rev Immunol* 2000;18:767-811.
- [95] Grouard G, Risoan MC, Filgueira L, Durand I, Banchereau J, et al. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med* 1997;185:1101-11.
- [96] Holt PG, Haining S, Nelson DJ, Sedgwick JD. Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. *J Immunol* 1994;153:256-61.
- [97] McWilliam AS, Nelson D, Thomas JA, Holt PG. Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces. *J Exp Med* 1994;179:1331-6.
- [98] Legge KL, Braciale TJ. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. *Immunity* 2003;18:265-77.
- [99] Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. *Nat Immunol* 2005;6:1029-37.
- [100] Swain SL, McKinsty KK, Strutt TM. Expanding roles for CD4(+) T cells in immunity to viruses. *Nat Rev Immunol* 2012;12:136-48.
- [101] Cousens LP, Peterson R, Hsu S, Dorner A, Altman JD, et al. Two roads diverged: interferon alpha/beta- and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. *J Exp Med* 1999;189:1315-28.

- [102] Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. *Cell* 1997;89:587-96.
- [103] Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. *J Exp Med* 2012;209:1241-53.
- [104] Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. *J Exp Med* 2002;196:247-53.
- [105] Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* 2003;4:330-6.
- [106] Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. *Nat Rev Immunol* 2002;2:735-47.
- [107] Wiesel M, Walton S, Richter K, Oxenius A. Virus-specific CD8 T cells: activation, differentiation and memory formation. *APMIS* 2009;117:356-81.
- [108] Chan KS, Kaur A. Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques. *J Immunol Methods* 2007;325:20-34.
- [109] Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. *Cell Mol Immunol* 2009;6:15-25.
- [110] Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med* 2013;19:1305-12.

- [111] Boon AC, de Mutsert G, Graus YM, Fouchier RA, Sintnicolaas K, et al. The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype. *J Virol* 2002;76:582-90.
- [112] Gotch F, McMichael A, Smith G, Moss B. Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes. *J Exp Med* 1987;165:408-16.
- [113] Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. *J Virol* 1998;72:8682-9.
- [114] McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. *N Engl J Med* 1983;309:13-7.
- [115] McGill J, Van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. *J Exp Med* 2008;205:1635-46.
- [116] Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. *J Immunol* 1997;159:5197-200.
- [117] de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, et al. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. *J Exp Med* 2005;202:1433-42.
- [118] Hogan RJ, Usherwood EJ, Zhong W, Roberts AA, Dutton RW, et al. Activated antigen-specific CD8+ T cells persist in the lungs following recovery from respiratory virus infections. *J Immunol* 2001;166:1813-22.
- [119] Piet B, de Bree GJ, Smids-Dierdorp BS, van der Loos CM, Remmerswaal EB, et al. CD8(+) T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. *J Clin Invest* 2011;121:2254-63.

- [120] Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, et al. The chemokine receptor CCR5 plays a key role in the early memory CD8<sup>+</sup> T cell response to respiratory virus infections. *Immunity* 2008;29:101-13.
- [121] Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. *Immunity* 2013;39:939-48.
- [122] Ray SJ, Franki SN, Pierce RH, Dimitrova S, Kotliansky V, et al. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. *Immunity* 2004;20:167-79.
- [123] Crispe IN. The liver as a lymphoid organ. *Annu Rev Immunol* 2009;27:147-63.
- [124] Gao B, Jeong WI, Tian Z. Liver: An organ with predominant innate immunity. *Hepatology* 2008;47:729-36.
- [125] Wang B, Trippler M, Pei R, Lu M, Broering R, et al. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. *J Hepatol* 2009;51:1037-45.
- [126] Wu J, Lu M, Meng Z, Trippler M, Broering R, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. *Hepatology* 2007;46:1769-78.
- [127] Lee LY, Ha do LA, Simmons C, de Jong MD, Chau NV, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. *J Clin Invest* 2008;118:3478-90.
- [128] Preiss S, Thompson A, Chen X, Rodgers S, Markovska V, et al. Characterization of the innate immune signalling pathways in hepatocyte cell lines. *J Viral Hepat* 2008;15:888-900.

- [129] Lech M, Avila-Ferrufino A, Skuginna V, Susanti HE, Anders HJ. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. *Int Immunol* 2010;22:717-28.
- [130] Takeuchi O, Akira S. Innate immunity to virus infection. *Immunol Rev* 2009;227:75-86.
- [131] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012;57:167-85.
- [132] McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. *Hepatol Int* 2009;3:334-42.
- [133] Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. *Br Med J* 1978;2:1056-8.
- [134] Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol* 2005;5:215-29.
- [135] Urbani S, Amadei B, Cariani E, Fiscaro P, Orlandini A, et al. The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. *J Immunol* 2005;175:7519-29.
- [136] Boni A, Fiscaro P, Valdatta C, Amadei B, Di Vincenzo P, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. *J Virol* 2007;81:4215-25.
- [137] Ferrari C, Penna A, Bertolotti A, Valli A, Antoni AD, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. *J Immunol* 1990;145:3442-9.

- [138] Jung MC, Spengler U, Schraut W, Hoffmann R, Zachoval R, et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. *J Hepatol* 1991;13:310-7.
- [139] Ferrari C, Bertolotti A, Penna A, Cavalli A, Valli A, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. *J Clin Invest* 1991;88:214-22.
- [140] Bocher WO, Herzog-Hauff S, Schlaak J, Meyer zum Buschenfeld KH, Lohr HF. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the *in vitro* antibody response by interferon gamma. *Hepatology* 1999;29:238-44.
- [141] Penna A, Artini M, Cavalli A, Levrero M, Bertolotti A, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. *J Clin Invest* 1996;98:1185-94.
- [142] Rehmann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. *Nat Med* 1996;2:1104-8.
- [143] Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. *Hepatology* 2000;32:1117-24.
- [144] Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. *J Virol* 1995;69:3358-68.
- [145] Bertolotti A, Ferrari C, Fiaccadori F, Penna A, Margolske R, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously



synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 1991;88:10445-9.

- [146] Rehermann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996;97:1655-65.
- [147] Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91.
- [148] Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36.
- [149] Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999;284:825-9.
- [150] Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-19.
- [151] Bertolotti A, Costanzo A, Chisari FV, Levrero M, Artini M, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994;180:933-43.
- [152] Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995;96:1527-34.
- [153] Beignon AS, McKenna K, Skoberne M, Manches O, DaSilva I, et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005;115:3265-75.

- [154] Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, et al. Innate sensing of HIV-infected cells. *PLoS Pathog* 2011;7:e1001284.
- [155] Boasso A, Herbeuval JP, Hardy AW, Anderson SA, Dolan MJ, et al. HIV inhibits CD4<sup>+</sup> T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. *Blood* 2007;109:3351-9.
- [156] Royle CM, Graham DR, Sharma S, Fuchs D, Boasso A. HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs. *J Immunol* 2014;193:3538-48.
- [157] Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. *J Immunol* 2008;181:5396-404.
- [158] Manches O, Munn D, Fallahi A, Lifson J, Chaperot L, et al. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. *J Clin Invest* 2008;118:3431-9.
- [159] El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, et al. T-cell exhaustion in HIV infection. *Curr HIV/AIDS Rep* 2008;5:13-9.
- [160] Yoo J, Chen H, Kraus T, Hirsch D, Polyak S, et al. Altered cytokine production and accessory cell function after HIV-1 infection. *J Immunol* 1996;157:1313-20.
- [161] Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, et al. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. *J Clin Virol* 2003;26:247-63.
- [162] Harrison TS, Kornfeld H, Levitz SM. The effect of infection with human immunodeficiency virus on the anticryptococcal activity of lymphocytes and monocytes. *J Infect Dis* 1995;172:665-71.

- [163] Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? *Immunol Today* 1993;14:161-4.
- [164] Cooper A, Garcia M, Petrovas C, Yamamoto T, Koup RA, et al. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. *Nature* 2013;498:376-9.
- [165] Nardacci R, Perfettini JL, Grieco L, Thieffry D, Kroemer G, et al. Syncytial apoptosis signaling network induced by the HIV-1 envelope glycoprotein complex: an overview. *Cell Death Dis* 2015;6:e1846.
- [166] Mohan T, Bhatnagar S, Gupta DL, Rao DN. Current understanding of HIV-1 and T-cell adaptive immunity: progress to date. *Microb Pathog* 2014;73:60-9.
- [167] Morou A, Palmer BE, Kaufmann DE. Distinctive features of CD4+ T cell dysfunction in chronic viral infections. *Curr Opin HIV AIDS* 2014;9:446-51.
- [168] Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprovicz V, Nolan BE, et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. *J Exp Med* 2012;209:61-75.
- [169] Doering TA, Crawford A, Angelosanto JM, Paley MA, Ziegler CG, et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. *Immunity* 2012;37:1130-44.
- [170] Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. *Trends Immunol* 2014;35:51-60.
- [171] Frederiksen J, Buggert M, Noyan K, Nowak P, Sonnerborg A, et al. Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily

Associated with the CD4/CD8 Ratio in Chronic HIV Infection. PLoS One 2015;10:e0137635.

- [172] Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. *Immunity* 2014;40:289-302.
- [173] Marchetti G, Gazzola L, Trabattoni D, Bai F, Ancona G, et al. Skewed T-cell maturation and function in HIV-infected patients failing CD4+ recovery upon long-term virologically suppressive HAART. *AIDS* 2010;24:1455-60.
- [174] Wodarz D, Klenerman P, Nowak MA. Dynamics of cytotoxic T-lymphocyte exhaustion. *Proc Biol Sci* 1998;265:191-203.
- [175] Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. *Nature* 2001;410:106-11.
- [176] Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, et al. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. *Pediatrics* 2006;118:e315-22.
- [177] Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. *Vaccine* 2009;27:17-22.
- [178] Malaspina A, Moir S, Chaitt DG, Rehm CA, Kottlilil S, et al. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. *Blood* 2007;109:2086-8.

- [179] Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. *J Exp Med* 2008;205:1797-805.
- [180] Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. *Immunity* 2007;27:670-84.
- [181] Klein MB, Lu Y, DelBalso L, Cote S, Boivin G. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. *Clin Infect Dis* 2007;45:234-40.
- [182] Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. *Clin Infect Dis* 2000;31:604-6.
- [183] Baker M, Kelly H, Wilson N. Pandemic H1N1 influenza lessons from the southern hemisphere. *Euro Surveill* 2009;14.
- [184] Sheth AN, Althoff KN, Brooks JT. Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature. *Clin Infect Dis* 2011;52:219-27.
- [185] Cohen C, Simonsen L, Sample J, Kang JW, Miller M, et al. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. *Clin Infect Dis* 2012;55:996-1003.
- [186] Neuzil KM, Coffey CS, Mitchel EF, Jr., Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. *J Acquir Immune Defic Syndr* 2003;34:304-7.
- [187] Sheth AN, Patel P, Peters PJ. Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic. *Curr HIV/AIDS Rep* 2011;8:181-91.

- [188] Dhanireddy S, Harrington RD, Crane HM, Gingo MR, Morris A, et al. Pandemic (H1N1) 2009 and HIV Infection. *Emerg Infect Dis* 2011;17:1140-3.
- [189] de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nat Med* 2006;12:1203-7.
- [190] Sansonetti P, Sali M, Fabbiani M, Morandi M, Martucci R, et al. Immune response to influenza A(H1N1)v in HIV-infected patients. *J Infect Dev Ctries* 2014;8:101-9.
- [191] Israel N, Hazan U, Alcamí J, Munier A, Arenzana-Seisdedos F, et al. Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens. *J Immunol* 1989;143:3956-60.
- [192] Twu JS, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. *Proc Natl Acad Sci U S A* 1989;86:5168-72.
- [193] Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-kappaB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. *J Biol Chem* 2001;276:35435-43.
- [194] Tsai MS, Chang SY, Lo YC, Yang CJ, Sun HY, et al. Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. *J Infect Dis* 2013;208:1184-6.
- [195] Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. *J Infect Dis* 2012;205:185-93.

- [196] Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. *J Infect Dis* 2013;208:1454-8.
- [197] Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. *J Infect Dis* 1991;163:1138-40.
- [198] Hadler SC, Judson FN, O'Malley PM, Altman NL, Penley K, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. *J Infect Dis* 1991;163:454-9.
- [199] Couch RB, Kasel JA. Immunity to influenza in man. *Annu Rev Microbiol* 1983;37:529-49.
- [200] Ennis FA, Mayner RE, Barry DW, Manischewitz JE, Dunlap RC, et al. Correlation of laboratory studies with clinical responses to A/New Jersey influenza vaccines. *J Infect Dis* 1977;136 Suppl:S397-406.
- [201] Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. *Scand J Immunol* 2004;59:1-15.
- [202] Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012;12:36-44.
- [203] Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, et al. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. *Vaccine* 2013;31:6030-3.
- [204] Ferguson M, Risi G, Davis M, Sheldon E, Baron M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1

2009 pandemic influenza vaccine with or without AS03 adjuvant. *J Infect Dis* 2012;205:733-44.

- [205] Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. *Nat Med* 2012;18:274-80.
- [206] Spensieri F, Borgogni E, Zedda L, Bardelli M, Buricchi F, et al. Human circulating influenza-CD4+ ICOS1+IL-21+ T cells expand after vaccination, exert helper function, and predict antibody responses. *Proc Natl Acad Sci U S A* 2013;110:14330-5.
- [207] Crowe BA, Bruhl P, Gerencer M, Schwendinger MG, Pilz A, et al. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans. *Vaccine* 2010;29:166-73.
- [208] Moris P, van der Most R, Leroux-Roels I, Clement F, Drame M, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. *J Clin Immunol* 2011;31:443-54.
- [209] Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. *J Virol* 2007;81:8468-76.
- [210] Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. *J Infect Dis* 2011;204:845-53.
- [211] Rey D, Krantz V, Partisani M, Schmitt MP, Meyer P, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. *Vaccine* 2000;18:1161-5.



- [212] Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results. *Vaccine* 1998;16:1933-5.
- [213] Dienstag JL, Werner BG, Polk BF, Snyderman DR, Craven DE, et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. *Ann Intern Med* 1984;101:34-40.
- [214] Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med* 1986;315:209-14.
- [215] Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2011;60:1-45.
- [216] Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. *Vaccine* 2013;31:1040-4.
- [217] Carollo M, Palazzo R, Bianco M, Pandolfi E, Chionne P, et al. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. *Vaccine* 2013;31:506-13.
- [218] Honorati MC, Dolzani P, Mariani E, Piacentini A, Lisignoli G, et al. Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. *Gastroenterology* 1997;112:2017-27.
- [219] Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, et al. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. *Vaccine* 2011;29:9209-13.

- [220] Fabbiani M, Sidella L, Corbi M, Martucci R, Sali M, et al. HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects. *Vaccine* 2013;31:2914-8.
- [221] Manuel O, Pascual M, Hoschler K, Giulieri S, Alves D, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. *Clin Infect Dis* 2011;52:248-56.
- [222] Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. *AIDS* 1998;12:F217-23.
- [223] Agrati C, Castilletti C, Cimini E, Lapa D, Quartu S, et al. Cellular and humoral cross-immunity against two H3N2v influenza strains in presumably unexposed healthy and HIV-infected subjects. *PLoS One* 2014;9:e105651.
- [224] Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep* 2009;58:1-207; quiz CE1-4.
- [225] Tayal SC, Sankar KN. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals. *AIDS* 1994;8:558-9.
- [226] da Mota Silveira Sasaki MG, Sobroza De Mello R, Focaccia Siciliano R, Wang L. Response of HIV/AIDS Patients to Hepatitis B Recombinant Vaccine. *Braz J Infect Dis* 1998;2:236-40.
- [227] Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. *Vaccine* 2005;23:2902-8.

- [228] Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. *PLoS One* 2013;8:e80409.
- [229] Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. *JAMA* 2011;305:1432-40.
- [230] Okulicz JF, Mesner O, Ganesan A, O'Bryan TA, Deiss RG, et al. Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers. *PLoS One* 2014;9:e105591.
- [231] Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. *J Immune Based Ther Vaccines* 2008;6:4.
- [232] Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehmann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. *Blood* 2004;104:478-86.
- [233] Howe R, Dillon S, Rogers L, Palmer B, MaWhinney S, et al. Phenotypic and functional characterization of HIV-1-specific CD4+CD8+ double-positive T cells in early and chronic HIV-1 infection. *J Acquir Immune Defic Syndr* 2009;50:444-56.
- [234] Peiris JS, Poon LL, Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. *J Clin Virol* 2009;45:169-73.
- [235] Chowell G, Bertozzi SM, Colchero MA, Lopez-Gatell H, Alpuche-Aranda C, et al. Severe respiratory disease concurrent with the circulation of H1N1 influenza. *N Engl J Med* 2009;361:674-9.

- [236] Writing Committee of the WHO CoCoA oPI, Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. *N Engl J Med* 2010;362:1708-19.
- [237] Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. *J Clin Invest* 1989;84:1892-9.
- [238] Blauvelt A, Clerici M, Lucey DR, Steinberg SM, Yarchoan R, et al. Functional studies of epidermal Langerhans cells and blood monocytes in HIV-infected persons. *J Immunol* 1995;154:3506-15.
- [239] Twigg HL, 3rd, Weissler JC, Yoffe B, Ball EJ, Lipscomb MF. Monocyte accessory cell function in patients infected with the human immunodeficiency virus. *Clin Immunol Immunopathol* 1991;59:436-48.
- [240] Macatonia SE, Lau R, Patterson S, Pinching AJ, Knight SC. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. *Immunology* 1990;71:38-45.
- [241] Agrati C, Gioia C, Castilletti C, Lapa D, Berno G, et al. Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients. *AIDS Res Hum Retroviruses* 2012;28:1606-16.
- [242] Fritz S, Mossdorf E, Durovic B, Zenhausern G, Conen A, et al. Viroosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy. *AIDS* 2010;24:2287-9.
- [243] Weinberg A, Muresan P, Fenton T, Richardson K, Dominguez T, et al. High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088). *Hum Vaccin Immunother* 2013;9:957-68.

- [244] Miraglia JL, Abdala E, Hoff PM, Luiz AM, Oliveira DS, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. *PLoS One* 2011;6:e27214.
- [245] Watcharananan SP, Thakkestian A, Srichunrasmee C, Chuntratita W, Sumethkul V. Comparison of the immunogenicity of a monovalent influenza A/H1N1 2009 vaccine between healthy individuals, patients with chronic renal failure, and immunocompromised populations. *Transplant Proc* 2014;46:328-31.
- [246] Viganò A, Zuccotti GV, Pacei M, Erba P, Castelletti E, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. *J Acquir Immune Defic Syndr* 2008;48:289-96.
- [247] Hamann D, Baars PA, Rep MH, Hooibrink B, Kerkhof-Garde SR, et al. Phenotypic and functional separation of memory and effector human CD8<sup>+</sup> T cells. *J Exp Med* 1997;186:1407-18.
- [248] Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 1999;401:708-12.
- [249] Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, et al. CD4<sup>+</sup> T-cell memory: generation and multi-faceted roles for CD4<sup>+</sup> T cells in protective immunity to influenza. *Immunol Rev* 2006;211:8-22.
- [250] Kohlmeier JE, Woodland DL. Immunity to respiratory viruses. *Annu Rev Immunol* 2009;27:61-82.
- [251] Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. *J Clin Invest* 1998;101:746-54.

- [252] Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. *Immunity* 2013;38:187-97.
- [253] Tu W, Mao H, Zheng J, Liu Y, Chiu SS, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. *J Virol* 2010;84:6527-35.
- [254] Brainard DM, Tager AM, Misdraji J, Frahm N, Lichterfeld M, et al. Decreased CXCR3+ CD8 T cells in advanced human immunodeficiency virus infection suggest that a homing defect contributes to cytotoxic T-lymphocyte dysfunction. *J Virol* 2007;81:8439-50.
- [255] Mavigner M, Cazabat M, Dubois M, L'Faqihi FE, Requena M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. *J Clin Invest* 2012;122:62-9.
- [256] Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, et al. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. *Blood* 2001;98:156-64.
- [257] Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. *J Virol* 2004;78:630-41.
- [258] Roman E, Miller E, Harmsen A, Wiley J, Von Andrian UH, et al. CD4 effector T cell subsets in the response to influenza: heterogeneity, migration, and function. *J Exp Med* 2002;196:957-68.
- [259] Ohnuki K, Watanabe Y, Takahashi Y, Kobayashi S, Watanabe S, et al. Antigen-specific CD4+ effector T cells: analysis of factors regulating clonal expansion and cytokine production: clonal expansion and cytokine

production by CD4<sup>+</sup> effector T cells. *Biochem Biophys Res Commun* 2009;380:742-7.

- [260] Laouar Y, Crispe IN. Functional flexibility in T cells: independent regulation of CD4<sup>+</sup> T cell proliferation and effector function in vivo. *Immunity* 2000;13:291-301.
- [261] Chandrasekaran P, Moore V, Buckley M, Spurrier J, Kehrl JH, et al. HIV-1 Nef down-modulates C-C and C-X-C chemokine receptors via ubiquitin and ubiquitin-independent mechanism. *PLoS One* 2014;9:e86998.
- [262] DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. *N Engl J Med* 2014;371:635-45.
- [263] Nace DA, Lin CJ, Ross TM, Saracco S, Churilla RM, et al. Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities. *J Infect Dis* 2014.
- [264] Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. *J Infect Dis* 2009;200:172-80.
- [265] Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, et al. A novel influenza A (H1N1) vaccine in various age groups. *N Engl J Med* 2009;361:2414-23.
- [266] Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, et al. Immunogenicity and safety of the influenza A/H1N1 2009 inactivated split-virus vaccine in young and older adults: MF59-adjuvanted vaccine versus nonadjuvanted vaccine. *Clin Vaccine Immunol* 2011;18:1358-64.
- [267] Brownstein JS, Kleinman KP, Mandl KD. Identifying pediatric age groups for influenza vaccination using a real-time regional surveillance system. *Am J Epidemiol* 2005;162:686-93.

- [268] Tempia S, Walaza S, Viboud C, Cohen AL, Madhi SA, et al. Mortality associated with seasonal and pandemic influenza and respiratory syncytial virus among children <5 years of age in a high HIV prevalence setting--South Africa, 1998-2009. *Clin Infect Dis* 2014;58:1241-9.
- [269] Loeb M, Russell ML, Moss L, Fonseca K, Fox J, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. *JAMA* 2010;303:943-50.
- [270] Stanekova Z, Vareckova E. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. *Virology* 2010;7:351.
- [271] Kim TS, Sun J, Braciale TJ. T cell responses during influenza infection: getting and keeping control. *Trends Immunol* 2011;32:225-31.
- [272] Chandanayingyong D, Stephens HA, Klaythong R, Sirikong M, Udee S, et al. HLA-A, -B, -DRB1, -DQA1, and -DQB1 polymorphism in Thais. *Hum Immunol* 1997;53:174-82.
- [273] Fongsatikul L, Nantachit N, Kamtorn N, Leetrakool N. HLA gene frequencies of northern Thais. *J Med Assoc Thai* 1997;80 Suppl 1:S38-42.
- [274] Greiner J, Schleiermacher E, Lenhard V, Kulapongs P, Vogel F. HLA antigen, gene, and haplotype frequencies in Thailand. *Hum Genet* 1978;41:73-87.
- [275] Kupatawintu P, Pheanchaen S, Srisuddee A, Tanaka H, Tadokoro K, et al. HLA-A, -B, -DR haplotype frequencies in the Thai Stem Cell Donor Registry. *Tissue Antigens* 2010;75:730-6.
- [276] Simmerman JM, Chittaganpitch M, Levy J, Chantra S, Maloney S, et al. Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005-2008. *PLoS One* 2009;4:e7776.



- [277] Tanzi E, Esposito S, Bojanin J, Amendola A, Trabattoni D, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. *J Med Virol* 2006;78:440-5.
- [278] Lambe T, Spencer AJ, Mullarkey CE, Antrobus RD, Yu LM, et al. T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine. *Pediatr Infect Dis J* 2012;31:e86-91.
- [279] Hsu JP, Phoon MC, Koh GC, Chen MI, Lee VJ, et al. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. *Int J Infect Dis* 2012;16:e621-7.
- [280] Thomas DL, Cannon RO, Shapiro CN, Hook EW, 3rd, Alter MJ, et al. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. *J Infect Dis* 1994;169:990-5.
- [281] Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. *Lancet Infect Dis* 2007;7:402-9.
- [282] Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection--a global challenge. *N Engl J Med* 2012;366:1749-52.
- [283] Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jouglu E, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. *J Hepatol* 2005;42:799-805.
- [284] Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). *Lancet* 2002;360:1921-6.

- [285] Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, et al. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. *Clin Infect Dis* 2014;58:1308-11.
- [286] Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. *MMWR Recomm Rep* 2009;58:1-207; quiz CE1-4.
- [287] Geretti AM, Committee BIW, Brook G, Cameron C, Chadwick D, et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. *HIV Med* 2008;9:795-848.
- [288] Bruguera M, Cremades M, Salinas R, Costa J, Grau M, et al. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. *J Clin Gastroenterol* 1992;14:27-30.
- [289] Keet IP, van Doornum G, Safary A, Coutinho RA. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. *AIDS* 1992;6:509-10.
- [290] Landrum ML, Huppler Hullsiek K, Ganesan A, Weintrob AC, Crum-Cianflone NF, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. *Vaccine* 2009;27:4731-8.
- [291] Tsai IJ, Chang MH, Chen HL, Ni YH, Lee PI, et al. Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults. *Vaccine* 2000;19:437-41.

- [292] Bruguera M, Bayas JM, Vilella A, Tural C, Gonzalez A, et al. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults. *Vaccine* 1996;14:1407-11.
- [293] Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. *MMWR Recomm Rep* 2006;55:1-33; quiz CE1-4.
- [294] McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. *Nat Rev Immunol* 2012;12:24-34.
- [295] Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. *J Virol* 2003;77:2469-76.
- [296] Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. *Proc Natl Acad Sci U S A* 1994;91:3764-8.
- [297] Stoop JN, Woltman AM, Biesta PJ, Kusters JG, Kuipers EJ, et al. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response. *Hepatology* 2007;46:699-705.
- [298] Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol* 2012;12:180-90.
- [299] Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. *Cytokine* 2004;28:109-23.
- [300] Litjens NH, Huisman M, Hijdra D, Lambrecht BM, Stittelaar KJ, et al. IL-2 producing memory CD4+ T lymphocytes are closely associated with the generation of IgG-secreting plasma cells. *J Immunol* 2008;181:3665-73.

- [301] De Rosa SC, Lu FX, Yu J, Perfetto SP, Falloon J, et al. Vaccination in humans generates broad T cell cytokine responses. *J Immunol* 2004;173:5372-80.
- [302] Divekar AA, Zaiss DM, Lee FE, Liu D, Topham DJ, et al. Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. *J Immunol* 2006;176:1465-73.
- [303] Kim HN, Harrington RD, Van Rompaey SE, Kitahata MM. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. *Int J STD AIDS* 2008;19:600-4.
- [304] Jarrosson L, Kolopp-Sarda MN, Aguilar P, Bene MC, Lepori ML, et al. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. *Vaccine* 2004;22:3789-96.

## LIST OF PUBLICATIONS

- 1) Chawansuntati K, Chotirosniramit N, Sugandhavesa P, Aурpibul L, Thetket S, et al. Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation *in vitro* following H1N1 vaccination of HIV-infected individuals. *Hum Vaccin Immunother* 2015; 11:2253-65.
- 2) Chawansuntati K, Aурpibul L, Wipasa J. Vaccination for 2009 pandemic H1N1 influenza A did not induce conserved epitope-specific memory CD8 T cell responses in HIV+ northern Thai children. *Vaccine* 2015; 33:4741-4.
- 3) Wipasa J, Wongkulab P, Chawansuntati K, Chaiwarit R, Supparatpinyo K. Cellular immune responses in HIV-negative immunodeficiency with anti-interferon-gamma antibodies and opportunistic intracellular microorganisms. *PLoS One* 2014; 9:e110276.
- 5) Wipasa J, Okell L, Sakkhachornphop S, Suphavailai C, Chawansuntati K, et al. Short-lived IFN-gamma effector responses, but long-lived IL-10 memory responses, to malaria in an area of low malaria endemicity. *PLoS Pathog* 2011; 7:e1001281.
- 6) Koosirirat C, Linpisarn S, Changsom D, Chawansuntati K, Wipasa J. Investigation of the anti-inflammatory effect of *Curcuma longa* in *Helicobacter pylori*-infected patients. *Int Immunopharmacol* 2010;10:815-8.
- 7) Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. *Science* 2010; 328:745-8